News
Some individuals living with obesity and overweight may find it difficult to embark on a weight loss journey alone. It’s not ...
Ozempic is an FDA-approved medication for people who have type 2 diabetes. It’s often prescribed “off-label” for weight loss ...
New cash pay program offers Contrave, the #1 branded oral non-GLP-1 weight loss medication brand, for as low as $199 per ...
Novo Nordisk is in the lead, but not alone. Obesity doctors say they are gearing up for demand, predicted to be high. Some ...
In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic ...
The U.S. Food and Drug Administration (FDA) has approved a new drug that can be used as a weight-loss medication. Wegovy is specifically for chronic weight management in overweight or obese adults ...
FDA approves new version of diabetes drug Mounjaro for weight loss Zepbound, a new version of the popular diabetes treatment Mounjaro, received government approval Wednesday to be sold as a weight ...
The FDA approved the weight-loss drug Wegovy as a treatment to reduce cardiovascular risk in adults who are overweight, the first approval of its kind. Accessibility statement Skip to main content.
The Food and Drug Administration (FDA) approved Eli Lilly’s blockbuster diabetes drug for weight loss management Wednesday, giving patients another tool and opening the door to potentially much ...
FDA approves diabetes drug for weight loss Published: Nov. 09, 2023, 6:50 a.m. This image provided by Eli Lilly on Wednesday, Nov. 8, 2023 shows packaging for their new drug Zepbound.
Are any weight loss pills FDA approved? "Over-the-counter supplements for weight loss should be viewed with caution because at best, they don't work, and at worst, they may cause harm," warns Patel.
The U.S. Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the weight-loss drug Zepbound. The medicine, part of the class known as GLP-1 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results